Trial Profile
A Randomised, Multicentre, Open Label, Phase II study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib with Capecitabine for the Treatment of Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Octreotide (Primary) ; Octreotide (Primary) ; Capecitabine; Lapatinib
- Indications Diarrhoea
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK; Novartis Pharmaceuticals
- 18 Dec 2021 This trial has been completed in Italy (global end date: 19 Oct 2019), according to European Clinical Trials Database record.
- 02 May 2019 This trial has been completed in France. (global end date: 19 Oct 2019)
- 28 Mar 2019 This trial has been completed in UK - MHRA according to European Clinical Trials Database record.